TICKERNERD
Menu
HTFLHTFLHealthcare · Health Information Services

HTFL Stock Forecast: HeartFlow, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$50
+0.90% on the day

The 9 Wall Street analysts covering HeartFlow, Inc. hold a median 12-month price target of $45 — -10.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$4.3B
Ticker Nerd rank
39 / 100
Median analyst target
$45
Analysts covering
9
Revenue$52.6M+41.3% y/y
Operating income−$22.0M
Net income−$27.4M
Free cash flow−$32.0M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.7%
1M
+108.1%
YTD
+72.2%
1Y
+72.1%
From 52W high
0.0%
From 52W low
+145.0%
$20
$50
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

HTFL stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores HeartFlow, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
97
Issuance
70
Accruals
57
Quality
39
Value
38
Momentum
36
Size
26
Volatility
11
Growth
8

Revisions (97): Analysts have, on balance, been raising their forecasts.

Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

HTFL stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on HTFL, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$25$30$35$40$45$50$55Oct 25Jan 26Apr 26Jul 26HTFLHigh $45Median $45Low $39

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says9 analysts
8 Buy1 Hold0 Sell
Low $39Median $45High $45

The green dot is the last close — the median target sits −10.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
14 Aug 2026Canaccord GenuityMaintainsBuy$37 → $45
14 Aug 2026JP MorganMaintainsOverweight$35 → $45
14 Aug 2026Morgan StanleyMaintainsEqual-Weight$35 → $40
14 Aug 2026Piper SandlerReiteratesOverweight$38 → $45
14 Aug 2026StifelMaintainsBuy$40 → $45
14 Aug 2026Wells FargoMaintainsOverweight$37 → $39
31 July 2026BairdInitiatesOutperform$34
31 July 2026BairdInitiatesOutperform—
1 July 2026Freedom Capital MarketsInitiatesBuy$37
1 July 2026Freedom Capital MarketsInitiatesBuy—
15 May 2026Canaccord GenuityMaintainsBuy—
15 May 2026Wells FargoMaintainsOverweight—
4 May 2026William BlairInitiatesOutperform—
19 Mar 2026Canaccord GenuityMaintainsBuy—
19 Mar 2026JP MorganMaintainsOverweight—
19 Mar 2026Wells FargoMaintainsOverweight—
9 Mar 2026Canaccord GenuityMaintainsBuy—
28 Jan 2026Wells FargoInitiatesOverweight—
13 Nov 2025Canaccord GenuityMaintainsBuy—
13 Nov 2025JP MorganMaintainsOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. HTFL appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

HTFL vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, HeartFlow, Inc. returned +72.1% against +19.6% for the S&P 500, dividends included.

HTFL vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Oct 25Jan 26Apr 26Jul 26HTFLS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

HTFL analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
3
Analysts cutting
0
Fundamentals

HeartFlow, Inc. (HTFL) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.7×

Cheaper than 95% of US stocks

Price / sales
20.4×

Cheaper than 9% of US stocks

Price / book
15.4×

Cheaper than 7% of US stocks

EV / EBITDA
−58.7×

Cheaper than 94% of US stocks

Growth & margins
Revenue growth (YoY)
47.6%

Higher than 85% of US stocks

Earnings growth (YoY)
41.3%

Higher than 72% of US stocks

Gross margin
80.2%

Higher than 91% of US stocks

Operating margin
−27.9%

Higher than 20% of US stocks

Net margin
−55.8%

Higher than 9% of US stocks

Returns & dividend
Return on equity
−154.2%

Higher than 9% of US stocks

Return on assets
−18.1%

Higher than 21% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

HeartFlow, Inc. (HTFL) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • HeartFlow, Inc. has a market value of $4.3B and an enterprise value of $4.2B.

  • Revenue in the twelve months to 31 Mar 2026: $191.4M. The latest quarter grew 47.6% year on year.

  • Net income over the same four quarters: −$111.8M, a −58.4% net margin.

  • Diluted earnings per share, trailing twelve months: $−1.76.

  • Free cash flow in the twelve months to 31 Mar 2026: −$76.8M, after $5.8M of capital spending.

  • Shares outstanding: 86.1M.

  • Trailing P/E: −15.7×; forward P/E: −188.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • HeartFlow, Inc. employs 843 people — $227K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

HTFL vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
HTFLHeartFlow, Inc.$4.3B
39
DOCSDoximity, Inc.$4.7B
61
WAYWaystar Holding Corp.$4.8B
34
HNGEHinge Health, Inc.$6.8B
82
PRVAPrivia Health Group, Inc.$2.6B
70
TXG10X Genomics, Inc.$8.1B
94
HQYHealthEquity, Inc.$9.0B
95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own HeartFlow, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest HTFL news & analysis

HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?

The Motley Fool · 20 Aug 2026neutral

HeartFlow's chief medical officer sold 9,219 shares at $41.23 per share on August 17, 2026, generating roughly $380,100. The sale reduced the insider's direct equity position by 10% and total beneficial ownership by 4%.

Why it matters — A HeartFlow watcher would care because this insider sale by a top executive could be watched for signals about insider sentiment toward the stock.

HeartFlow: An Impressive MedTech Growth Play

Seeking Alpha · 16 Aug 2026positive

HeartFlow reported a strong second quarter with 48% sales growth and gross margins rising to 83%. The company raised its full-year revenue guidance to $246-$250 million, and shares are trading at 13x sales amid accelerating topline growth and expanding plaque-related revenue.

Why it matters — HeartFlow watchers would track this item because it highlights strong quarterly performance, improved margins, and raised guidance for the company's non-invasive cardiac solution.

Why Heartflow Stock Soared Today

The Motley Fool · 14 Aug 2026positive

HeartFlow's stock rose sharply today. The company's AI-powered platform could save many lives, and the business continues to grow at a strong pace.

Why it matters — The stock's jump and continued growth reflect growing attention on HeartFlow's AI-driven heart-care technology.

HeartFlow Shares Soar Following Strong Q2 Results and Upgraded Guidance

Benzinga · 14 Aug 2026positive

HeartFlow Inc. reported better-than-expected second-quarter adjusted EPS results and raised its full-year financial outlook. Following the announcement, the company's shares traded sharply higher Friday afternoon.

Why it matters — The stronger-than-expected results and upgraded annual guidance point to improved financial performance, and the sharp share price increase reflects a notable market response.

This AI-Tied IPO Stock Just Broke Out On Its 'Outsized' Guidance Boost

Investors Business Daily · 14 Aug 2026positive

HeartFlow stock broke out on Friday after the company raised its guidance and beat second-quarter expectations. The guidance increase was described as "outsized."

Why it matters — The breakout and strong guidance raise signal improving financial momentum for HeartFlow, which could attract more investor attention.

FAQ

Frequently asked questions about HTFL stock

What is the HTFL stock price forecast for 2026-2027?

The 9 Wall Street analysts covering HeartFlow, Inc. have a median 12-month price target of $45, with estimates ranging from $39 to $45. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is HTFL stock a buy right now?

Of the 9 analysts covering HeartFlow, Inc., 8 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks HeartFlow, Inc. 39 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank HTFL?

As at 22 Aug 2026, HeartFlow, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (97 of 100).

Will HTFL stock go up?

No one can know that. What the data says: the median 12-month target from 9 analysts implies -10.4% from the last close, and Ticker Nerd's factor model ranks HeartFlow, Inc. 39 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the HTFL stock forecast for 2030?

No analyst covering HeartFlow, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for HTFL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $39 to $45 over the next 12 months.

How has HTFL stock performed over the past year?

HeartFlow, Inc. returned +72.1% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does HeartFlow, Inc. do?

HeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions.

What is the latest news on HTFL?

The most recent item we track (The Motley Fool, 20 Aug 2026): "HeartFlow's Chief Medical Officer Sells 9,219 Shares Amid a Soaring Stock Price. What Does That Mean for Investors?". HeartFlow's chief medical officer sold 9,219 shares at $41.23 per share on August 17, 2026, generating roughly $380,100. The sale reduced the insider's direct equity position by 10% and total beneficial ownership by 4%.

Company

About HeartFlow, Inc.

HeartFlow, Inc. is a medical technology company specializing in precision heart care through advanced AI-powered software solutions. It transforms coronary computed tomography angiography (CCTA) scans into detailed 3D models of patients' coronary arteries, enabling non-invasive assessment of coronary artery disease (CAD). Key products include Roadmap Analysis for efficient CAD detection, FFRCT Analysis to evaluate blood flow and revascularization needs, and Plaque Analysis to quantify and characterize plaque for risk assessment and disease management. The integrated HeartFlow One platform supports clinicians in identifying, deciding, and managing CAD, optimizing patient care pathways with personalized insights. HeartFlow also provides comprehensive support services, including clinical, operational, technical, and financial resources to help institutions build scalable CCTA programs. Headquartered in Redwood City, California, the company plays a pivotal role in advancing proactive, patient-centered coronary care by empowering healthcare providers with innovative tools to detect, understand, and treat CAD effectively.

CEO Mr. John C.M. Farquhar · 843 employees · United States · https://www.heartflow.com